Cadila Healthcare

From Wikipedia, the free encyclopedia
  (Redirected from Zydus Cadila)
Jump to navigation Jump to search

Cadila Healthcare Limited
Public
Traded as
IndustryPharmaceuticals
Founded1952
FounderRamanbhai Patel
HeadquartersAhmedabad, Gujarat, India
Key people
Pankaj R. Patel, Chairman, Sharvil P. Patel, Managing Director
RevenueIncrease7,104.30 crore (US$1.0 billion) [1] (2019)
1,602.10 crore (US$220 million) [2] (2019)
Number of employees
13180 (2015)
Websitewww.zyduscadila.com

Cadila Healthcare Limited (also known as Zydus Cadila) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat, India,[3] with revenues of ₹7,104.30 crore (US$1.0 billion) in 2019.[4] It is a manufacturer of generic drugs.[5]

History[edit]

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321.

In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.[6]

In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.

In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand name Exemptia at one-fifth the originator's price.[7] Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015.[5]

In 2019, injectable ketorolac tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.

In 2020, Zydus Cadila's drug Desidustat received approval by the USFDA to initiate clinical trials on cancer patients. [8]

Products[edit]

From nine pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment (i.e. sofosbuvir, distributed under the brand name SoviHep).[9]

The company makes active pharmaceutical ingredients at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.

COVID-19 vaccine development[edit]

In July 2020, the company got permission to conduct human trials of the developmental COVID-19 vaccine named ZyCoV-D, from the Drugs Controller General of India (DCGI), Government of India.[10][11][12]

Cadila is also among the several Indian pharma companies that received the licensing agreements from the Gilead Sciences to produce remdesivir[13]

Corporate control[edit]

Zydus Cadila's major shareholder remains the Patel family. Pankaj Patel (born 1951), son of the founder, is the chairman of the company. In 2004, Pankaj Patel was included in Forbes' annual list of India's richest people. As of 2020, Forbes estimates Patel's net worth at US $3.9 billion, making him India's 46th richest person.[14]

References[edit]

  1. ^ "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  2. ^ "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  3. ^ "A Complete Overview on Cadila Healthcare, a growing and popular company in India". business.mapsofindia.com. 21 June 2011. Retrieved 4 February 2009.
  4. ^ "Cadila Healthcare Profit and Loss Reports - The Economic Times". economictimes.indiatimes.com. Retrieved 15 June 2020.
  5. ^ a b "Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences". The Hindu Business Line. 17 March 2015. Retrieved 29 December 2017.
  6. ^ Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda Bloomberg
  7. ^ Zydus Cadila launches biosimilar of AbbVie's Humira in India The Economic Times 9 December 2014
  8. ^ Zydus Cadila Desidustat Gets USFDA Nod To Initiate Clinical Trials On Cancer Patients The Times Of India 23 July 2020
  9. ^ "Hepatitis C treatment in India for less than $1000". hep-c-news.com. Hep C News. 11 July 2016. Archived from the original on 16 September 2016.
  10. ^ "Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials". The Hindu. 3 July 2020.
  11. ^ "Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld". ETHealthworld.com.
  12. ^ "Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial". The New York Times. 5 August 2020.
  13. ^ Umarji, Vinay (12 June 2020). "Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila". Business Standard India.
  14. ^ "Pankaj Patel". Forbes. Retrieved 15 June 2020.

External links[edit]